Infinity Pharmaceuticals, Inc. INFI today announced that the company
amended its development and license agreement with Millennium: The Takeda
Oncology Company and Takeda Pharmaceutical Company Limited (TSE:4502) for
Infinity's phosphoinositide-3-kinase (PI3K) program. Under the amended
agreement, Infinity continues to retain full worldwide rights to IPI-145, a
potent, oral inhibitor of PI3K-delta and PI3K-gamma, as well as worldwide
rights to any future product candidates targeting PI3K-delta and/or
PI3K-gamma, and Millennium remains entitled to receive success-based
milestones and tiered royalties on future worldwide sales of products covered
by this agreement. In exchange for Infinity's one-time payment of $15 million,
Millennium waived its right to opt into a 50-50 U.S. profit and loss-sharing
arrangement in the U.S. for any of Infinity's PI3K inhibitors, including
IPI-145. In addition, Infinity paid Millennium the $5 million development
milestone for the August 2012 initiation of the Phase 2a clinical trial of
IPI-145 in patients with asthma.
Terms of the Amendment to Development and License Agreement
Under the terms of the amended agreement, Infinity continues to retain
worldwide development and commercialization rights for its PI3K-delta,gamma
program. In exchange for Infinity's one-time payment of $15 million,
Millennium waived its right to opt into a 50-50 U.S. profit and loss-sharing
arrangement and its right to participate in up to 30 percent of the detailing
effort in the U.S. for any of Infinity's PI3K inhibitors. In addition,
Infinity paid Millennium the $5 million milestone for the August 2012
initiation of the Phase 2a trial of IPI-145 in patients with asthma.
For Infinity's first two distinct PI3K product candidates, Millennium is
entitled to receive up to $15 million in remaining success-based development
milestones and up to $450 million in success-based approval and commercial
milestones, as defined in the original agreement. For all of Infinity's
PI3K-delta and/or PI3K-gamma inhibitors covered under the agreement, Infinity
is obligated to pay Millennium tiered royalties on worldwide net sales ranging
from seven percent to 11 percent, which are the same royalty levels as those
specified under the original agreement.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in